About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

Kidney Disease Clinical Trials in San Antonio | 151 Studies | Clareo Health

Clinical Trials Kidney DiseaseSan Antonio

Kidney Disease Clinical Trials in San Antonio

Find 151 clinical trials for kidney disease near San Antonio, Texas. Connect with research centers in your area.

All Kidney Disease trials nationwide All trials in San Antonio

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 141-151 of 151 trials

COMPLETEDPHASE1< 1 mile

Safety Study of GCS-100 to Treat Chronic Kidney Disease

NCT01717248

The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.

Chronic Kidney Disease

La Jolla Pharmaceutical Company29 participantsStarted Jan 2013

Tempe, Arizona, United States • La Mesa, California, United States • Denver, Colorado, United States +1 more locations

COMPLETEDPHASE3< 1 mile

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597753

The purpose of the study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.

Chronic Renal FailureChronic Kidney DiseaseAnemia

Affymax803 participantsStarted Sep 2007

Paragould, Arkansas, United States • Fairfield, California, United States • Granada Hills, California, United States +86 more locations

Kidney Disease Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPHASE3< 1 mile

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598442

The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA) treatment.

Chronic Renal FailureChronic Kidney DiseaseAnemia

Affymax493 participantsStarted Nov 2007

Phoenix, Arizona, United States • Fayetteville, Arkansas, United States • Fountain Valley, California, United States +61 more locations

COMPLETEDPHASE2< 1 mile

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

NCT00014144

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.

Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer

SWOG Cancer Research Network31 participantsStarted Feb 2001

Birmingham, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +92 more locations

COMPLETEDPHASE4< 1 mile

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

NCT00977080

Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.

Chronic Kidney DiseaseSecondary HyperparathyroidismHemodialysis

Abbott272 participantsStarted Nov 2009

Tempe, Arizona, United States • Chula Vista, California, United States • Los Angeles, California, United States +80 more locations

COMPLETEDPHASE174 miles

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

NCT00501462

This is an open-label study that will measure blood levels of different parts of a drug called GKS189075. People participating in this study will receive a single dose of 250mg GSK189075 by mouth. About 20 people with mild to moderate decrease in renal (kidney) function will be asked to participate in this study. They will be compared to about 20 healthy participants who are close to the same age and body size. People participating in this study will stay at a clinical research unit beginning 2 days before they receive their single dose of GSK189075 and will remain there until approximately one day after receiving the study drug. During this study urine will be collected beginning the day before receiving study drug until the day after, just prior to leaving the clinical research unit. Blood samples will also be collected at various times beginning immediately before until 24 hours after receiving the study drug.

Type 2 Diabetes MellitusDiabetes Mellitus, Type 2Renal Insufficiency

GlaxoSmithKline29 participantsStarted Jul 2007

Orlando, Florida, United States • Minneapolis, Minnesota, United States • Knoxville, Tennessee, United States +1 more locations

COMPLETEDPHASE2190 miles

Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

NCT00486538

This study is designed to determine the clinical efficacy and toxicity of ABT 869 in the treatment of subjects with advanced renal cell carcinoma who have previously received treatment with sunitinib.

Advanced Renal Cell Carcinoma

AbbVie (prior sponsor, Abbott)53 participantsStarted Jun 2007

Sacramento, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +10 more locations

COMPLETEDPHASE3190 miles

Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

NCT00033904

Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.

Renal Cell Carcinoma

Agenus Inc.650 participantsStarted Jun 2000

Anchorage, Alaska, United States • Tucson, Arizona, United States • Los Angeles, California, United States +73 more locations

COMPLETEDPHASE4190 miles

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

NCT00863707

This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.

Kidney DiseasesCoronary Artery Disease

Astellas Pharma Inc511 participantsStarted Apr 2009

Anniston, Alabama, United States • Little Rock, Arkansas, United States • Bell Gardens, California, United States +38 more locations

UNKNOWNPHASE3190 miles

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

NCT00628680

The purpose of this study is to determine if AAT-023 (Zuragen) solution is superior to Heparin in preventing Catheter Related Blood Stream Infections for End Stage Renal Disease patients.

End Stage Renal Disease

Ash Access Technology415 participantsStarted Jul 2006

Bakersfield, California, United States • Lynwood, California, United States • Middlebury, Connecticut, United States +19 more locations

COMPLETEDPHASE1/PHASE2190 miles

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168

Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced kidney injury and resultant delayed graft function (DGF). PSGL-1 is a ligand for P-, E-, and L-selectin. It has been reported that YSPSL (rPSGL-Ig) blocks P-selectin and, to a lesser degree, E- and L-selectin. Both sPSGL-1 and YSPSL (rPSGL-Ig) have been shown in animal models to reduce both cytokines and tissue damage associated with ischemia reperfusion and to improve renal function post-transplant. Therefore, the current phase I/II clinical study is designed to assess the safety and efficacy of YSPSL (rPSGL-Ig) in preventing DGF in patients undergoing cadaveric kidney transplants and to determine a dose for future pivotal studies.

Kidney Diseases

Y's Therapeutics, Inc.60 participantsStarted May 2006

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +12 more locations

PreviousPage 8 of 8

Other Conditions in San Antonio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia